Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · IEX Real-Time Price · USD
8.59
-0.20 (-2.28%)
At close: Aug 8, 2022 4:00 PM
8.70
+0.11 (1.28%)
After-hours: Aug 8, 2022 7:56 PM EDT
-2.28%
Market Cap 715.18M
Revenue (ttm) 285.38M
Net Income (ttm) 48.40M
Shares Out 83.26M
EPS (ttm) 0.54
PE Ratio 15.91
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 484,294
Open 8.90
Previous Close 8.79
Day's Range 8.59 - 8.92
52-Week Range 5.31 - 46.91
Beta n/a
Analysts Sell
Price Target 7.65 (-10.9%)
Earnings Date Aug 8, 2022

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formula... [Read more...]

Industry Pharmaceuticals
IPO Date Oct 30, 2020
Employees 64
Stock Exchange NASDAQ
Ticker Symbol AVIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AVIR stock is "Sell." The 12-month stock price forecast is 7.65, which is a decrease of -10.94% from the latest price.

Price Target
$7.65
(-10.94% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and aud...

Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executiv...

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executiv...

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.0...

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual ...

Bemnifosbuvir Demonstrated Favorable Overall Nonclinical Safety Profile, Including Lack of Reproductive and Development Toxicity in Animal Models Bemnifosbuvir Demonstrated Favorable Overall Nonclinical...

Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains?

Atea Pharmaceuticals, Inc. (AVIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p...

Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours Winner

The stock market was mixed on Monday as investors tried to reconcile everything happening around the world.

Other symbols: ZM

Dow Jones Newswires: Atea Pharma stock jumps as earnings rise, potential COVID-19 therapy advances

Shares of Atea Pharmaceuticals Inc. were trading over 18% higher in the after-hours market Monday, following the company's release of fourth-quarter financial results and news of upcoming drug trials.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022

Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting th...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. ("Atea" or the "Company") (NASDAQ: AVIR). Such invest...

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NAS...

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

COVID-19 : Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials

Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executiv...

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Bi...

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527

Implied Volatility Surging for Atea (AVIR) Stock Options

Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.

Atea Pharmaceuticals - Boom and Bust in Biotechland

Atea Pharmaceuticals Inc. ( AVIR , Financial) is a Boston-based clinical stage biotech company which became public in November of 2020 and quickly raised over $300 million cash.

Why Atea Pharmaceuticals Stock Is Sinking Today

Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and aud...

Is There Any Hope for Atea Pharmaceuticals Stock?

If its coronavirus pill project can't be salvaged, it'll be trouble for investors.